Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?
Roland Seiler(University of British Columbia), P. Black, Hung‐Ming Lam(Seattle Pacific University), Mandeep Takhar(Genome British Columbia), Ewan A. Gibb(BC Cancer Agency), Ellen C. Zwarthoff(Erasmus MC), N. Erho, Htoo Zarni Oo(University of British Columbia), Kim van Kessel(Erasmus MC Cancer Institute), E. Fransen Van De Putte, G. Thalmann, N.Q. Wang, Gottfrid Sjödahl(Lund University), Simon J. Crabb(University of Southampton), Joost L. Boormans(Erasmus MC), Marc Dall’Era(University of California, Davis), Brian Winters(University of Washington), M. van der Heijden(The Netherlands Cancer Institute), J. Douglas, Jay Wright, Bas van Rhijn(The Netherlands Cancer Institute), Elai Davicioni(Coherus BioSciences (United States))
Cited by 0
Related Papers
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma
|Cancer Cell|2017|2.1k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
A Molecular Taxonomy for Urothelial Carcinoma
|Clinical Cancer Research|2012|1k